Brodalumab

證據等級: L5

預測適應症: 10 個

Brodalumab: From Plaque Psoriasis to Strongyloidiasis

One-Sentence Summary

Brodalumab is a fully human monoclonal antibody targeting the IL-17 receptor A (IL-17RA), approved in multiple countries for moderate-to-severe plaque psoriasis, but not yet marketed in Taiwan. The TxGNN model ranks Strongyloidiasis as its top predicted new indication (score: 99.84%), yet this prediction is supported by 0 clinical trials and 0 publications — and raises significant mechanistic safety concerns rather than a genuine therapeutic opportunity.

Quick Overview

Item	Content
Original Indication	Moderate-to-severe plaque psoriasis (not approved in Taiwan)
Predicted New Indication	Strongyloidiasis
TxGNN Prediction Score	99.84%
Evidence Level	L5
Taiwan Market Status	✗ Not Marketed
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Brodalumab is a fully human IgG2 monoclonal antibody that binds to IL-17 receptor A (IL-17RA) — the shared signaling receptor for multiple IL-17 family cytokines including IL-17A, IL-17F, IL-17C, and IL-25 (IL-17E). By blocking IL-17RA, Brodalumab broadly suppresses downstream IL-17-driven inflammatory signaling. Its efficacy in plaque psoriasis is well-established (AMAGINE-1/-2/-3 Phase 3 trials), and it is approved under the brand names Siliq, Kyntheum, and Lumicef in the US, EU, and Japan respectively.

However, the prediction linking Brodalumab to strongyloidiasis is mechanistically counter-indicated. Strongyloides stercoralis infection is primarily cleared through Th2-driven immunity — specifically IL-4, IL-5, and IL-13 — and eosinophil activation. IL-17 plays only a minor, secondary role in helminth defense. Critically, blockade of IL-17RA may impair eosinophil recruitment and mucus barrier function, which are essential for parasite expulsion. Rather than treating strongyloidiasis, Brodalumab could theoretically worsen the infection or — in immunocompromised patients — precipitate hyperinfection syndrome, a potentially fatal disseminated form of the disease.

This prediction is highly likely a knowledge graph traversal artifact: a false positive generated by indirect node connections in the TxGNN graph that do not reflect a real pharmacological relationship. The risk-benefit profile is negative, not neutral, for this specific indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Brodalumab is currently not marketed in Taiwan. No drug licenses have been issued by the Taiwan Food and Drug Administration (TFDA). Safety and prescribing information currently needs to be referenced from foreign regulatory authorities (US FDA, EMA, PMDA).

Safety Considerations

Please refer to the package insert for safety information.

Contextual note for this prediction: In the specific context of strongyloidiasis, the immunosuppressive mechanism of Brodalumab (IL-17RA blockade) presents a potential safety hazard. Biologic immunosuppression is a well-recognized risk factor for Strongyloides hyperinfection syndrome. This safety signal further reinforces the Hold recommendation for this indication.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction sits at the lowest evidence tier (L5 — model prediction only) with zero supporting clinical or preclinical data, and the mechanistic rationale actively argues against the repurposing hypothesis: suppressing IL-17RA signaling in the setting of an active parasitic infection is more likely to worsen host defense than to provide therapeutic benefit.

To proceed, the following is needed:

Retrieve complete MOA and safety data from DrugBank to close the two flagged data gaps (DG001: TFDA package insert warnings/contraindications; DG002: mechanism of action)
Formally classify this prediction as a graph traversal artifact and deprioritize it from further evaluation
Consider redirecting analysis effort toward the rank-2 prediction (Eye Disease, L4), which carries a biologically plausible mechanistic link via the role of IL-17 in uveitis and dry eye disease, and has at least one supporting clinical trial and one review publication
If the eye disease indication is pursued, retrieve class-effect data from secukinumab and ixekizumab trials in uveitis (SpA-related) to support an indirect evidence bridge

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.